Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates
Authors:
- 1 December 2015
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 220, 5-17
Abstract
No abstract availableKeywords
Funding Information
- National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2012ZX09103301-030)
- China Postdoctoral Science Foundation (2015T80983)
This publication has 45 references indexed in Scilit:
- Synthesis, characterization, and antitumor evaluation of the albumin–SN38 conjugateAnti-Cancer Drugs, 2013
- Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-αBMC Cancer, 2012
- Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivoBreast Cancer Research, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Research and Treatment, 2010
- Preparative isolation and purification of anti‐tumor agent ansamitocin P‐3 from fermentation broth of Actinosynnema pretiosum using high‐performance counter‐current chromatographyJournal of Separation Science, 2010
- CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 ImmunoconjugatesClinical Cancer Research, 2009
- Changes inHER2Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and18F-Labeled Affibody MoleculesJournal of Nuclear Medicine, 2009
- Liposomalization of SN-38 as active metabolite of CPT-11Journal of Controlled Release, 2005
- A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) in human plasma containing liposome‐based SN‐38 (LE‐SN38)Biomedical Chromatography, 2003